Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets
Citations Over TimeTop 1% of 2017 papers
Abstract
The decreasing cost of genomic technologies has enabled the molecular characterization of large-scale clinical disease samples and of molecular changes upon drug treatment in various disease models. Exploring methods to relate diseases to potentially efficacious drugs through various molecular features is critically important in the discovery of new therapeutics. Here we show that the potency of a drug to reverse cancer-associated gene expression changes positively correlates with that drug's efficacy in preclinical models of breast, liver and colon cancers. Using a systems-based approach, we predict four compounds showing high potency to reverse gene expression in liver cancer and validate that all four compounds are effective in five liver cancer cell lines. The in vivo efficacy of pyrvinium pamoate is further confirmed in a subcutaneous xenograft model. In conclusion, this systems-based approach may be complementary to the traditional target-based approach in connecting diseases to potentially efficacious drugs.
Related Papers
- → Uncomfortably high: Testing reveals inflated THC potency on retail Cannabis labels(2023)39 cited
- → The potency of bovine PPD tuberculins in guinea-pigs and in tuberculous cattle(1983)18 cited
- → Establishment of a Potency Test by ELISA for a Rabies Vaccine for Animal Use in Japan(2003)15 cited
- → Potency analysis of cellular therapies: the role of molecular assays(2021)
- → Application of Emax model to assess the potency of topical corticosteroid products(2022)